- Home
- PBYI vs FENC Comparison
PBYI vs FENC Comparison
Compare PBYI & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- FENC
- Stock Information
- Founded
- PBYI 2010
- FENC 1996
- Country
- PBYI United States
- FENC United States
- Employees
- PBYI N/A
- FENC N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PBYI Health Care
- FENC Health Care
- Exchange
- PBYI Nasdaq
- FENC Nasdaq
- Market Cap
- PBYI 263.4M
- FENC 234.9M
- IPO Year
- PBYI N/A
- FENC 2001
- Fundamental
- Price
- PBYI $4.91
- FENC $8.01
- Analyst Decision
- PBYI Strong Buy
- FENC Strong Buy
- Analyst Count
- PBYI 1
- FENC 2
- Target Price
- PBYI $7.00
- FENC $13.50
- AVG Volume (30 Days)
- PBYI 635.5K
- FENC 69.1K
- Earning Date
- PBYI 11-06-2025
- FENC 11-13-2025
- Dividend Yield
- PBYI N/A
- FENC N/A
- EPS Growth
- PBYI 59.87
- FENC N/A
- EPS
- PBYI 0.74
- FENC N/A
- Revenue
- PBYI $211,995,000.00
- FENC $38,790,000.00
- Revenue This Year
- PBYI N/A
- FENC N/A
- Revenue Next Year
- PBYI N/A
- FENC $64.79
- P/E Ratio
- PBYI $6.61
- FENC N/A
- Revenue Growth
- PBYI N/A
- FENC N/A
- 52 Week Low
- PBYI $2.32
- FENC $3.96
- 52 Week High
- PBYI $6.12
- FENC $9.92
- Technical
- Relative Strength Index (RSI)
- PBYI 46.97
- FENC 41.09
- Support Level
- PBYI $4.58
- FENC $7.53
- Resistance Level
- PBYI $6.12
- FENC $8.42
- Average True Range (ATR)
- PBYI 0.40
- FENC 0.47
- MACD
- PBYI -0.05
- FENC -0.04
- Stochastic Oscillator
- PBYI 20.06
- FENC 20.86
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.